STOCK TITAN

Establishment Labs to Present at the Jefferies Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that its CEO, Juan José Chacón-Quirós, and CFO, Raj Denhoy will present at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 am Eastern Time. A live webcast will be available on the company's investor relations website, with an archived version accessible afterward. Founded to enhance women's health, Establishment Labs specializes in breast aesthetics and reconstruction, offering innovative products like Motiva Implants®, with 2 million units distributed globally since 2010.

Positive
  • None.
Negative
  • None.

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 10:30 am Eastern Time.

A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, approximately 2.0 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Motiva MIA®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva Implants® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

Investor/Media Contact:

Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

When is Establishment Labs presenting at the Jefferies Healthcare Conference?

Establishment Labs will present at the Jefferies Healthcare Conference on June 8, 2022, at 10:30 am Eastern Time.

Who will represent Establishment Labs at the Jefferies Healthcare Conference?

The presentation will be made by CEO Juan José Chacón-Quirós and CFO Raj Denhoy.

Where can I watch the Establishment Labs presentation live?

The live webcast of the presentation will be available on the Establishment Labs investor relations website.

What products does Establishment Labs focus on?

Establishment Labs focuses on breast health, particularly in aesthetics and reconstruction, offering products like Motiva Implants®.

How many Motiva Implants® have been delivered globally?

Approximately 2.0 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries since their launch.

Establishment Labs Holdings Inc.

NASDAQ:ESTA

ESTA Rankings

ESTA Latest News

ESTA Stock Data

1.22B
24.52M
11.28%
92.31%
18.33%
Medical Devices
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States of America
ALAJUELA